Search

Ocular Therapeutix Inc

Suletud

SektorTervishoid

9.99 -1.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.88

Max

10.08

Põhinäitajad

By Trading Economics

Sissetulek

9.8M

-79M

Müük

2.7M

13M

Aktsiakasum

-0.35

Kasumimarginaal

-584.512

Töötajad

325

EBITDA

10M

-74M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+152.75% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

462M

2.4B

Eelmine avamishind

11.18

Eelmine sulgemishind

9.99

Uudiste sentiment

By Acuity

100%

0%

320 / 339 Pingereas Healthcare

Ocular Therapeutix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2026, 23:25 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, rising from a low post-close and currently above Friday's close but below its 20-day moving average.

17. sept 2026, 20:07 UTC

Ocular Therapeutix Inc is advancing, maintaining gains from Wednesday, despite earlier pulling back from a session high while remaining below its 20-day moving average.

16. sept 2026, 20:10 UTC

Event
Social Media

Ocular Therapeutix Inc shares fell sharply despite positive social media sentiment about its NDA filing for Axpaxli and recent FDA discussions.

15. sept 2026, 22:02 UTC

Event

Ocular Therapeutix Inc. plans to submit its New Drug Application by Q4 2026, but shares are lower in after-market hours amid broader economic concerns.

14. sept 2026, 19:17 UTC

Ocular Therapeutix Inc is trading higher during Monday's session, having gained since Friday's close, despite a negative broader market sentiment.

11. sept 2026, 23:51 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, supported by improved fiscal management reflected in a narrower-than-expected budget deficit of $167 billion for August.

10. sept 2026, 22:26 UTC

Ocular Therapeutix Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock retraced from an initial rise.

9. sept 2026, 23:36 UTC

Ocular Therapeutix shares are lower in after-market trading, continuing a decline since Wednesday's close, despite remaining near the upper end of their one-month range.

8. sept 2026, 20:02 UTC

Ocular Therapeutix Inc shares are higher during Tuesday's market hours, despite earlier pulling back from a session high. No specific news was identified.

3. sept 2026, 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2. sept 2026, 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1. sept 2026, 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31. aug 2026, 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28. aug 2026, 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27. aug 2026, 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26. aug 2026, 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24. aug 2026, 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22. aug 2026, 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21. aug 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20. aug 2026, 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19. aug 2026, 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18. aug 2026, 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17. aug 2026, 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14. aug 2026, 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13. aug 2026, 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12. aug 2026, 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11. aug 2026, 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10. aug 2026, 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7. aug 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6. aug 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Ocular Therapeutix Inc Prognoos

Hinnasiht

By TipRanks

152.75% tõus

12 kuu keskmine prognoos

Keskmine 25.25 USD  152.75%

Kõrge 31 USD

Madal 18 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

9

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

320 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.